Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer
Yan Huang,1,2,* Shuang Dai,1,2,* Wenlian Yin,3 Feng Luo,1,2 Yan Li2,4 1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-11-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/sustained-clinical-response-to-4th-line-therapy-with-selpercatinib-in--peer-reviewed-fulltext-article-OTT |
| _version_ | 1797447403677155328 |
|---|---|
| author | Huang Y Dai S Yin W Luo F Li Y |
| author_facet | Huang Y Dai S Yin W Luo F Li Y |
| author_sort | Huang Y |
| collection | DOAJ |
| description | Yan Huang,1,2,* Shuang Dai,1,2,* Wenlian Yin,3 Feng Luo,1,2 Yan Li2,4 1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 3Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 4Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan Li, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, People’s Republic of China, Email liyan1240@wchscu.cnObjective: Combined small cell lung cancer (C-SCLC) is a relatively rare subtype of small cell lung cancer (SCLC) which combines SCLC and any component of non-small cell carcinoma (NSCLC). Patients diagnosed with C-SCLC are currently recommended to receive the same treatment as SCLC cases in the absence of clear evidence suggesting different strategies. The genomic profiling of C-SCLC is rarely studied. Herein, we report a case of extensive-stage C-SCLC harboring the KIF5B-RET fusion before first-line therapy and with persistent sensitivity to fourth-line selpercatinib treatment is reported.Materials and Methods: Molecular and pathological features were evaluated using transbronchial lung biopsy, immunohistochemical (IHC) staining and next-generation sequencing (NGS).Results: NGS revealed the KIF5B-RET fusion in the C-SCLC tumor. The patient had a progression-free survival (PFS) surpassing 14 months after selpercatinib treatment, with ongoing clinical response in 4th-line treatment.Conclusion: This case highlights the importance of comprehensive molecular testing in C-SCLC for selecting the optimal treatment. Although RET fusion is rare in patients with C-SCLC, its identification and treatment with selective RET inhibitors may contribute to clinical benefits.Keywords: combined small cell lung cancer, rearranged during transfection, selpercatinib, next-generation sequencing |
| first_indexed | 2024-03-09T13:55:11Z |
| format | Article |
| id | doaj.art-8f71a277bfed462786078ea96f4529cf |
| institution | Directory Open Access Journal |
| issn | 1178-6930 |
| language | English |
| last_indexed | 2024-03-09T13:55:11Z |
| publishDate | 2023-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | OncoTargets and Therapy |
| spelling | doaj.art-8f71a277bfed462786078ea96f4529cf2023-11-30T18:44:06ZengDove Medical PressOncoTargets and Therapy1178-69302023-11-01Volume 161015102088593Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung CancerHuang YDai SYin WLuo FLi YYan Huang,1,2,* Shuang Dai,1,2,* Wenlian Yin,3 Feng Luo,1,2 Yan Li2,4 1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 3Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 4Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan Li, Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, People’s Republic of China, Email liyan1240@wchscu.cnObjective: Combined small cell lung cancer (C-SCLC) is a relatively rare subtype of small cell lung cancer (SCLC) which combines SCLC and any component of non-small cell carcinoma (NSCLC). Patients diagnosed with C-SCLC are currently recommended to receive the same treatment as SCLC cases in the absence of clear evidence suggesting different strategies. The genomic profiling of C-SCLC is rarely studied. Herein, we report a case of extensive-stage C-SCLC harboring the KIF5B-RET fusion before first-line therapy and with persistent sensitivity to fourth-line selpercatinib treatment is reported.Materials and Methods: Molecular and pathological features were evaluated using transbronchial lung biopsy, immunohistochemical (IHC) staining and next-generation sequencing (NGS).Results: NGS revealed the KIF5B-RET fusion in the C-SCLC tumor. The patient had a progression-free survival (PFS) surpassing 14 months after selpercatinib treatment, with ongoing clinical response in 4th-line treatment.Conclusion: This case highlights the importance of comprehensive molecular testing in C-SCLC for selecting the optimal treatment. Although RET fusion is rare in patients with C-SCLC, its identification and treatment with selective RET inhibitors may contribute to clinical benefits.Keywords: combined small cell lung cancer, rearranged during transfection, selpercatinib, next-generation sequencinghttps://www.dovepress.com/sustained-clinical-response-to-4th-line-therapy-with-selpercatinib-in--peer-reviewed-fulltext-article-OTTcombined small cell lung cancerrearranged during transfectionselpercatinibnext-generation sequencing |
| spellingShingle | Huang Y Dai S Yin W Luo F Li Y Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer OncoTargets and Therapy combined small cell lung cancer rearranged during transfection selpercatinib next-generation sequencing |
| title | Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer |
| title_full | Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer |
| title_fullStr | Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer |
| title_full_unstemmed | Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer |
| title_short | Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer |
| title_sort | sustained clinical response to 4th line therapy with selpercatinib in ret fusion positive combined small cell lung cancer |
| topic | combined small cell lung cancer rearranged during transfection selpercatinib next-generation sequencing |
| url | https://www.dovepress.com/sustained-clinical-response-to-4th-line-therapy-with-selpercatinib-in--peer-reviewed-fulltext-article-OTT |
| work_keys_str_mv | AT huangy sustainedclinicalresponseto4thlinetherapywithselpercatinibinretfusionpositivecombinedsmallcelllungcancer AT dais sustainedclinicalresponseto4thlinetherapywithselpercatinibinretfusionpositivecombinedsmallcelllungcancer AT yinw sustainedclinicalresponseto4thlinetherapywithselpercatinibinretfusionpositivecombinedsmallcelllungcancer AT luof sustainedclinicalresponseto4thlinetherapywithselpercatinibinretfusionpositivecombinedsmallcelllungcancer AT liy sustainedclinicalresponseto4thlinetherapywithselpercatinibinretfusionpositivecombinedsmallcelllungcancer |